Development of OCT and ED-71

Vitamin D

Volumn 2, Issue , 2005, Pages 1525-1541

  Kubodera, Noboru ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644997918     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50090-5     Document Type: Chapter

References (50)

1. 3. Proc Natl Acad Sci 1981, 78:4990-4994.
2. Bouillon R, Okamura WH, Norman AW Structure-function relationships in the vitamin D endocrine system. Endocrinology Rev 1995, 16:200-257.
3. 3 analogs. Chem Pharm Bull (Tokyo) 1986, 34:2286-2289.
4. 3 analogs. Chem Pharm Bull (Tokyo) 1986, 34:4410-4413.
5. 3. Chem Pharm Bull (Tokyo) 1991, 39:3221-3224.
6. 3. Chem Pharm Bull (Tokyo) 1992, 40:648-651.
7. 3 analogs. Chem Pharm Bull (Tokyo) 1992, 40:1494-1499.
8. Murayama E, Miyamoto K, Ochi K, Kubodera N Synthesis and immunoregulating activity of vitamin D analogs bearing pregnane, side chains. Bioorg Med Chem Lett 1992, 2:1289-1292.
9. 3 analogs. Bioorg Med Chem Lett 1993, 3:1869-1872.
10. 3 analogs and their 20( R)-epimers. Chem Pharm Bull (Tokyo) 1993, 41:1659-1663.
11. 3 and related analogs. Bioorg Med Chem Lett 1995, 5:279-282.
12. 3 with an oxygen atom in the side chain skeleton. FEBS Lett 1987, 226:58-62.
13. 3 (OCT) in rat parathyroid, kidney distal and proximal tubules, duodenum, and skin, studied by quantitative, receptor autoradiography. J Histochem Cytochem 1998, 46:1351-1358.
14. Kobayashi T, Okano T, Tsugawa N, Masuda S, Takeuchi A, Nishii Y Metabolism and transporting system of 22-oxacalcitriol. Comtrib Nephrol 1991, 91:129-133.
15. 3. J Nutr Sci Vitaminol 1989, 35:529-533.
16. Teramoto T, Endo K, Ikeda K, Kubodera N, Kinoshita M, Yamanaka M, Ogata E Binding of vitamin D to low-density-lipoprotein (LDL) and LDL receptor-mediated pathway into cells. Biochem Biophys Res Commun 1995, 215:199-204.
17. Miyamoto K, Kubodera N, Murayama E, Ochi K, Mori T, Matsunaga I Synthetic studies on vitamin D analogs VI. A new synthesis of 25-hydroxycholesterol from lithocholic acid. Syn Commun 1986, 16:513-521.
18. 3 analogs bearing a hydroxyalkoxy group at the 2β-position. Chem Pharm Bull (Tokyo) 1993, 41:1111-1113.
19. 3 analogs substituted at the 2β-position and their preventive effects on bone mineral loss in ovariectomized rats. Chem Pharm Bull (Tokyo) 1997, 45:1626-1630.
20. 3 (ED-71) on bone mineral loss in ovariectomized rats. Bioorg Med Chem 1998, 6:2517-2523.
21. 3. Biol Pharm Bull (Tokyo) 2000, 23:66-77.
22. 3 derivative, on calcium metabolism. Biochem Biophys Res Commun 1989, 163:1444-1449.
23. 3 (ED-71), preventive and therapeutic effects on bone mineral loss in ovariectomized rats. Bioorg Med Chem Lett 1993, 3:1815-1819.
24. Kubodera N, Sato K, Nishii Y Characteristics of 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)calcitriol (ED-71). Vitamin D 1997, 1071-1086. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
25. Mikami T, Iwaoka T, Kato M, Watanabe H, Kubodera N Practical formation of γ-keto or γ-hydroxy ether linkage from alcohol. Syn Commun 1997, 27:2363-2369.
26. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986, 78:1296-1301.
27. Sato K, Tominaga Y, Ichikawa F, Uchida K, Takezawa J, Tsuchiya T, Kubodera N, Takagi H In in vitro suppression of parathyroid hormone secretion by 22-oxa-calcitriol in human parathyroid hyperplasia due to uraemia. Nephrology 1998, 4:177-182.
28. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E The noncalcemic analogue of vitamin D,22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989, 84:728-732.
29. 3 in uremic rats: a possible mechanisms for less-calcemic action. Nephrology 1998, 4:391-395.
30. 3 regarding suppression of parathyroid hormone secretion and calcemic action in uraemic rats. Nephrol Dial Transplant 2002, 17(suppl 10):37-40.
31. 3 regarding suppression of parathyroid hormone and calcemic action. nephrol Dial Transplant 2002, 17(suppl 10):41-45.
32. 3 on secondary hyperparathyroidism in dogs with chronic renal failure. Nephrol Dial Transplant 2002, 17(suppl 10):46-52.
33. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993, 133:1158-1164.
34. Shibata S, Sakaguchi H, Nagasawa T, Naruse T Nephritogenic glycoprotein. II. Experimental production of membranous glomerulonephritis in rats by a single injection of homologous renal glycopeptde. Lab Invest 1972, 27:457-465.
35. Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999, 56:2040-2047.
36. Monier-Faugere M.-C, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999, 55:821-832.
37. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 1996, 11(Suppl 3):121-124.
38. 3 on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2002, 17(suppl 10):20-27.
39. 3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 2002, 17(suppl 10):28-36.
40. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kid Des 2000, 35:458-464.
41. 3 with oxygen atom in their side chain. Biochem Int 1989, 19:1143-1149.
42. Barker JNWN, Ashton RE, Marks R, Harris RI, Berth-Jones J Topical maxacalcitol for the treatment of psoriasis vulgaris: A placebo-controlled, double-blind, dose-finding study with active comparator. British J Dermatol 1999, 141:274-278.
43. 3 (ED-71). Bioorg Med Chem Lett 1997, 22:2871-2874.
44. 3 (24-hydroxylated ED-71). Steroids 2001, 66:267-276.
45. Shira-Ishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E Rationale for the advantage of alfacalcidol over native vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999, 65:311-316.
46. Shira-Ishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis. Distinct action from estrogen. J Bone Miner Res 2000, 15:770-779.
47. Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, Ogata E ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30:582-588.
48. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 1994, 54:142-149.
49. 3 (ED-71): A promising candidate for the treatment of osteoporosis. Proceedings of Eleventh Workshop on Vitamin D May 2000, 985-992. University of California, Riverside. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
50. Kubodera N, Tsuji N, Uchiyama Y, Endo K A new active vitamin D analog, ED-71, increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 2003, 88:286.